Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Reviva Pharmaceuticals logo — Next Generation Therapeutics to successfully address central...

Reviva Pharmaceuticals

Next Generation Therapeutics to successfully address central nervous system, metabolic and respiratory diseases.

Founded 2006 United States Cupertino, United States 18 employees Post-IPO Equity Biopharma, Biotechnology +2

General Information

Company Name Reviva Pharmaceuticals
Founded Year 2006
Location United States Cupertino, United States
Employees 18
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Reviva Pharmaceuticals. To contact Reviva Pharmaceuticals, visit revivapharma.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Reviva Pharmaceuticals

Reviva Pharmaceuticals, Inc., (Reviva) is a publicly traded, late-stage clinical development pharmaceutical company based in Santa Clara, California. The company is dedicated to addressing unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases. Led by a highly successful and experienced management team from the pharmaceutical industry, Reviva has a strong emphasis on speed without compromising quality in its product development model. The company boasts a robust patent portfolio and has several promising products in the pipeline at various stages of development. Reviva Pharmaceuticals was founded in 2006 and operates in the Biopharma, Biotechnology, Health Care, and Pharmaceutical industries. The company's lead product, RP5063, has completed global Phase 2 clinical trials with superior efficacy and safety profiles for schizophrenia and schizo-affective disorder. After a successful End of Phase 2 (EOP2) meeting with the U.S. FDA, Reviva is gearing up to commence global Phase 3 clinical trials for RP5063 in acute and maintenance phase schizophrenia patients. Additionally, the company has plans to develop RP5063 for bipolar disorder, major depressive disorder (MDD), Alzheimer’s psychosis/agitation (ADP), Parkinson’s psychosis (PDP), attention deficit hyperactivity disorder (ADD/ADHD), and autism spectrum. The most recent investment in Reviva Pharmaceuticals came in the form of a Post-IPO Equity investment on 21 August 2024, although the details of the investors involved were not specified. With its innovative pipeline and a management team known for successfully bringing drugs to the global market, Reviva Pharmaceuticals presents an exciting opportunity for potential investors in the pharmaceutical sector.

Taxonomy: clinical-stage biopharmaceutical, neuromodulator therapies, central nervous system diseases, respiratory diseases, metabolic diseases, chemical genomics driven technology, proprietary chemistry, drug development, clinical trials, patent portfolio, late-stage clinical development, multimodal neuromodulator, unmet medical needs, global market, pharmaceutical industry

Funding Rounds & Investors (9)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity Undisclosed -
21 Aug 2024
Post IPO Equity Undisclosed -
28 May 2024
Post IPO Equity Undisclosed -
16 Nov 2023
Post IPO Equity Undisclosed -
06 Sep 2022
Convertible Note Undisclosed -
23 May 2017
Convertible Note Undisclosed -
25 Jul 2016
Series D Undisclosed -
02 Jul 2014
Series C Undisclosed -
21 Mar 2013
Series B Undisclosed -
20 Aug 2012

Reviva Pharmaceuticals Alternatives & Competitors

Reviva Pharmaceuticals vs
Reistone Biopharma
Reistone Biopharma China

Focusing on rapidly developing innovative medicines through global collaborations within Research an...

Series A
52 employees
Biotechnology, Pharmaceutical
Reviva Pharmaceuticals vs
Relmada Therapeutics, Inc
Relmada Therapeutics, Inc United States

Relmada (Nasdaq: $RLMD) is a clinical-stage company developing novel therapies for the treatment of...

Post-IPO Equity
32 employees
Biotechnology, Pharmaceutical
Reviva Pharmaceuticals vs
Minerva Neurosciences
Minerva Neurosciences

Minerva Neurosciences, Inc. (NASDAQ: NERV) is a clinical-stage biopharmaceutical company focused on...

Post-IPO Equity
9 employees
Biopharma, Biotechnology

FAQ About Reviva Pharmaceuticals

Next Generation Therapeutics to successfully address central nervous system, metabolic and respiratory diseases.
Reviva Pharmaceuticals was founded in 2006.
Reviva Pharmaceuticals is headquartered in Cupertino, United States.
Reviva Pharmaceuticals operates in Biopharma, Biotechnology, Health Care and Pharmaceutical. Its work centres on clinical-stage biopharmaceutical, neuromodulator therapies, central nervous system diseases and respiratory diseases.
Reviva Pharmaceuticals has approximately 18 employees.
Reviva Pharmaceuticals has completed 9 funding rounds. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Reviva Pharmaceuticals include Reistone Biopharma, Relmada Therapeutics, Inc, Minerva Neurosciences, Ocuphire Pharma, Fabre-Kramer Pharmaceuticals, Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Reviva Pharmaceuticals and Reistone Biopharma are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Reviva Pharmaceuticals, https://bouncewatch.com/company/reviva-pharmaceuticals, updated 14 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes